Genmab wins a $10M milestone from J&J; Intec Pharma reports option deal;

@FierceBiotech: Amgen wins a much-needed FDA OK for heart drug ivabradine. Report | Follow @FierceBiotech

@JohnCFierce: The flimsy case for a miracle ALS drug collapses under expert scrutiny--Remember Genervon? ICYMI yesterday | Follow @JohnCFierce

> Danish biotech Genmab says will garner a $10 million milestone payment from J&J ($JNJ) for Phase III progress for daratumumab for multiple myeloma. Release

> Israel's Intec Pharma, which works on drug delivery tech, says it has gained a $1 million payment for an option deal with an unnamed pharma company. If the option is taken, the company adds, it will be in line for an $8 million upfront and $139 million in milestones. Release

Medical Device News

@FierceMedDev: ICYMI from FierceDiagnostics: GE and Veracyte team up for disease diagnostic research collaboration. Article | Follow @FierceMedDev

@VarunSaxena2: Devicemaker AngioDynamics invests in cancer drug delivery aspirant. FierceDrugDelivery story | Follow @VarunSaxena2

@EmilyWFierce: Congress spurs feds to investigate sky-high generic drug prices. More from FiercePharma | Follow @EmilyWFierce

> Citing power morcellator safety scare, insurance lobby calls for tougher regulation of devices. Story

> Startup gets CE mark for diabetic retinopathy screening software, FDA up next. Article

Pharma News

@FiercePharma: Nexvet regroups as key study on lead dog drug shows 'low probability' of success. FierceAnimalHealth report | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: Sounds like Walgreens would like to buy into another drug distributor like AmerisourceBergen. More | Follow @EricPFierce

@CarlyHFierce: Eisai rejig means sales-force downsizing at a critical moment for Arena's Belviq. FiercePharmaMarketing article | Follow @CarlyHFierce

> Pacira's Exparel marketing falls under Justice Department microscope. More

> Otsuka scrambles to persuade judge to block Abilify copycats. Report

CRO News

> Catalent wraps up a $52M manufacturing expansion. Item

> Quintiles deepens its Latin American ties with Argentine partnership. Article

> Two ophthalmology CROs join forces for ocular R&D. Report

> Aptuit pairs up with an Italian CRO for drug discovery. News

> Clinipace bags CRO Accovion in its latest global buyout. Story

Vaccines News

> Merck takes its Ebola vaccine to Phase III in Sierra Leone. Report

> Healthcare systems could benefit from covering HPV vaccine in boys, study says. Item

> Janssen looks to Ichor's electroporation delivery system for hep B jab. Story

> Aduro swings for the fences with $119M IPO. Article

> AstraZeneca's MedImmune gets RSV candidate fast-tracked. News

Pharma Manufacturing News

> Norwich Pharma spending $26M on new equipment. Item

> Sanofi Pasteur U.S. operation part of dengue vaccine buildup. More

> FDA stepping up efforts to replenish U.S. saline solution supplies. Article

> Bayer to pump $100M into U.S. facility focused on hemophilia drugs. Story

> GSK plant in Ireland making headway on reducing carbon footprint. Report

Pharma Asia News

> Quick China dealmaking as TVM, Lummy tie with Argos on oncology candidate. Article

> China's big pharma companies get thumbs-up from Moody's on reform push. News

> Australia to cut government benefits if parents don't vaccinate children. Report

> PerkinElmer gets China marketing authorization on Genetic Screening system. More

> Alibaba's latest move in China online drug sales is $2.51B shift of Tmall. Story

Suggested Articles

Forma's lead asset, an IDH1 inhibitor, cleared cancer in one-third of patients with relapsed or refractory acute myeloid leukemia.

A type of white blood cell known as a granulocyte secretes growth factors that help axons of the central nervous system regenerate, researchers found.

The deal, which features an additional $2 billion in milestones, will give Bayer control of an AAV platform and a clinical-phase pipeline.